Template:Travelers Diarrhea Antibiotics: Difference between revisions
Ostermayer (talk | contribs) (Created page with "*Ciprofloxacin 750mg PO BID x 1-3 days<ref>Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1...") |
(Convert to AntibioticDose with disease=Traveler's diarrhea) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
* | *{{AntibioticDose|disease=Traveler's diarrhea|drug=Ciprofloxacin|dose=750mg PO once daily x 1-3 days|context=Traveler's Diarrhea}}<ref>Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5</ref> | ||
* | **First choice for use except in South and Southeast Asia<ref>Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006</ref> | ||
* | *{{AntibioticDose|disease=Traveler's diarrhea|drug=Azithromycin|dose=500mg PO q24h x 3 days OR 1000mg PO x 1|context=Traveler's Diarrhea}}<ref>Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8</ref> | ||
**Nausea is a frequent adverse event<ref>Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006</ref> | |||
* | **First choice for use in South and Southeast Asia<ref>Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006</ref> | ||
*{{AntibioticDose|disease=Traveler's diarrhea|drug=Rifaximin|dose=200mg PO TID x 3 days|context=Traveler's Diarrhea}}<ref>DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15</ref> | |||
**Ineffective against mucosally invasive pathogens ([[Shigella]], [[Salmonella]], [[Campylobacter]]) | |||
**Considered very safe as it is not absorbed | |||
Latest revision as of 23:32, 19 March 2026
- Ciprofloxacin 750mg PO once daily x 1-3 days[1]
- First choice for use except in South and Southeast Asia[2]
- Azithromycin 500mg PO q24h x 3 days OR 1000mg PO x 1[3]
- Rifaximin 200mg PO TID x 3 days[6]
- Ineffective against mucosally invasive pathogens (Shigella, Salmonella, Campylobacter)
- Considered very safe as it is not absorbed
- ↑ Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5
- ↑ Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
- ↑ Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8
- ↑ Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
- ↑ Steffen R, et al. Traveler's Diarrhea: A Clinical Review. JAMA. 2015;313(1):71-80. doi:10.1001/jama.2014.17006
- ↑ DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15
